Home · Health · Sep 1 archive
Novartis, Bristol Myers Squibb Pause Cell Therapy Trials Due to Side Effects
Developing
Novartis and Bristol Myers Squibb have paused multiple trials evaluating their respective cell therapy programs against autoimmune conditions after observing inflammatory side effects in testing , BioPharma Dive reports.
Bristol Myers has also voluntarily paused enrollment in autoimmune trials evaluating its own CAR-T treatment zola-cel. To them we go … President Trump has announced the next round of pricing deals with drugmakers, with nine companies joining the 17 that reached agreements with the administration previously , STAT tells us.
What's confirmed
What's still developing
- To them we go … President Trump has announced the next round of pricing deals with drugmakers, with nine companies joining the 17 that reached agreements with the administration previously , STAT tells us.
- Novartis and Bristol Myers Squibb have paused multiple trials evaluating their respective cell therapy programs against autoimmune conditions after observing inflammatory side effects in testing , BioPharma Dive reports.
- Bristol Myers has also voluntarily paused enrollment in autoimmune trials evaluating its own CAR-T treatment zola-cel.
Sources
- STATlink